![Paolo Bernardi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Federica Draghi | M | - |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | 20 years |
Marco Giorgio | M | - |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | 20 years |
Pier Giuseppe Pelicci | M | - |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | 20 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paolo Fundarò | M | 50 |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Italy | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paolo Bernardi
- Personal Network